Kymera Therapeutics Inc share price logo

Kymera Therapeutics Inc Share Price

NASDAQ: KYMR

Mid Cap

$43.53

+1.33

(+3.15%)

as on

Kymera Therapeutics Inc Stock Performance

as on September 6, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $42.73
    $44
    downward going graph

    1.84%

    Downside

    1.08%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $19.45
    $53.27
    downward going graph

    55.33%

    Downside

    22.38%

    Upside

    downward going graph

Kymera Therapeutics Inc share price movements today

Previous Close
$42.20
Open
$42.81
Volume
453.6K
Day's Low - High
$42.73 - $44
52 Week Low - High
$19.45 - $53.27

Kymera Therapeutics Inc Historical Returns

1 Month Return
+ 5.22 %
3 Month Return
-8.63 %
1 Year Return
-4.16 %
3 Year Return
+ 67.93 %
5 Year Return
+ 47.24 %

Kymera Therapeutics Inc Stock Fundamentals & Key Indicators

Check Kymera Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.1B

EPS (TTM)

-3.3927

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-18.88

Industry PE ratio

-17.25

P/B Ratio

0

PEG Ratio

0

EBITDA

-305.1M

Revenue (TTM)

44.7M

Profit Margin

0.00%

Return On Equity TTM

26672600.00%

Kymera Therapeutics Inc Stock Valuation

Track how Kymera Therapeutics Inc P/E has moved over time to understand its valuation trends.

Kymera Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 6, 2025

Today (-18.88x)

September 6, 2025

Industry (-17.25x)

September 6, 2025

Highest (0.00x)

September 6, 2025

LowHigh

Today’s Price to Earnings Ratio: -18.88x

Kymera Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kymera Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$3.1B47.24%-18.880.00%
BUY$59.2B267.99%-505.15-12.96%
NA$38.1BNANA-3.89%
BUY$101.6B48.64%28.1931.86%
BUY$60.8B-1.2%14.4431.37%

Stock Returns calculator for Kymera Therapeutics Inc Stock including INR - Dollar returns

The Kymera Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Kymera Therapeutics Inc investment value today

Current value as on today

₹1,00,828

Returns

₹828

(+0.83%)

Returns from Kymera Therapeutics Inc Stock

₹4,119 (-4.12%)

Dollar Returns*

₹4,947 (+4.95%)

Analyst Recommendation on Kymera Therapeutics Inc Stock

Based on 23 analysts

BUY

69.57%

Buy

30.43%

Hold

0.00%

Sell

Based on 23 analysts, 69.57% of analysts recommend a 'BUY' rating for Kymera Therapeutics Inc. Average target price of $60.37

Kymera Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Kymera Therapeutics Inc.

What analysts predicted

27.89%UPSIDE

Target Price

$60.37

Current Price

$43.53

Analyzed by

23 Analysts

Target

$60.37

Kymera Therapeutics Inc target price $60.37, a slight upside of 27.89% compared to current price of $43.53. According to 23 analysts rating.

Kymera Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Kymera Therapeutics Inc Stock has increased by 82% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:82% versus previous 30 day period

Kymera Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
9
16
4
47
10
25
3
7
22
11
Gross Profit
8
15
3
47
10
25
3
7
22
9
Operating Income
-45
-43
-57
-19
-57
-50
-72
-80
-74
-84
EBITDA
-39
-37
-51
-13
-47
-40
-60
-68
-63
-84
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
1
1
1
1
2
2
Income Before Tax
-40
-38
-52
-14
-48
-42
-62
-70
-65
-76
Income Tax Expense
-4
4
0
4
0
-
-2
-
-
-
Net Income
-36
-38
-52
-14
-48
-42
-62
-70
-65
-76
Net Profit Margin
-386.49%
-234.96%
-1118.17%
-30.01%
-472.02%
-163.98%
-1670.33%
-956.88%
-296.75%
-667.60%

Kymera Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
2
34
72
46
78
47
Gross Profit
0
2
-28
70
43
78
47
Operating Income
-21
-42
-46
-100
-161
-165
-261
EBITDA
-21
-40
-43
-97
-151
-143
-216
Interest Expense
0
0
0
0
0
0
0
Depreciation
0
0
1
2
2
3
7
Income Before Tax
-21
-41
-45
-100
-154
-146
-223
Income Tax Expense
0
0
-1
-2
-2
18
-
Net Income
-21
-41
-43
-97
-151
-146
-223
Net Profit Margin
0.00%
-1407.36%
-129.12%
-134.55%
-324.25%
-186.99%
-475.57%

Kymera Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-38
-52
-14
-48
-42
-62
-70
-65
-76
Operating Cash Flow
-35
-31
8
-39
-42
-50
-61
-79
-59
Investing Cash Flow
35
60
18
-330
15
-157
68
48
60
Financing Cash Flow
1
0
1
353
1
250
2
0
245
Change in Cash
1
28
28
-16
-25
43
9
-30
245

Kymera Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-41
-45
-100
-154
-146
-223
Operating Cash Flow
17
88
-128
-153
-102
-194
Investing Cash Flow
-16
-422
-99
20
139
-404
Financing Cash Flow
34
289
250
152
4
608
Change in Cash
36
-45
21
20
41
10

Global Institutional Holdings in Kymera Therapeutics Inc

Funds
Holdings
T. Rowe Price Associates, Inc.
9.55%
venBio Select Advisor LLC
9.21%
Wellington Management Company LLP
8.55%
Baker Bros Advisors LP
8.55%
Vanguard Group Inc
7.46%

Insights on Kymera Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, KYMR stock has moved up by 2.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 80.4% return, outperforming this stock by 89.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 120.8% return, outperforming this stock by 67.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 22.1M → 11.47M (in $), with an average decrease of 48.1% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -65.58M → -76.61M (in $), with an average decrease of 16.8% per quarter

About Kymera Therapeutics Inc

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.
OrganisationKymera Therapeutics Inc
Headquarters500 North Beacon Street, Watertown, MA, United States, 02472
IndustryHealth Technology
CEODr. Nello Mainolfi M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Kymera Therapeutics Inc

Name

Title

Dr. Juliet Williams B.A Ph.D.

Head of Research

Dr. Bruce L. Booth DPHIL, Ph.D.

Co-Founder & Independent Chairman

Mr. Bruce N. Jacobs CFA

Chief Financial Officer

Ms. Ellen V. Chiniara Esq., J.D.

Chief Legal Officer & Corporate Secretary

Dr. Jared A. Gollob M.D.

Chief Medical Officer

Ms. Justine E. Koenigsberg

Vice President of Investor Relations

Ms. Karen Weisbach

Head of People & Culture

Mr. Noah Goodman M.B.A.

Chief Business Officer

Dr. Nello Mainolfi M.D., Ph.D.

Co-Founder, President, CEO & Director

Dr. Jeremy G. Chadwick Ph.D.

Chief Operating Officer

FAQs

What is Kymera Therapeutics Inc share price today?

Kymera Therapeutics Inc share price today is $43.53 as on at the close of the market. Kymera Therapeutics Inc share today touched a day high of $44 and a low of $42.73.

What is the 52 week high and 52 week low for Kymera Therapeutics Inc share?

Kymera Therapeutics Inc share touched a 52 week high of $53.27 on and a 52 week low of $19.45 on . Kymera Therapeutics Inc stock price today i.e. is closed at $43.53,which is 18.28% down from its 52 week high and 123.86% up from its 52 week low.

What is Kymera Therapeutics Inc's market capitalisation today?

Kymera Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Kymera Therapeutics Inc Stock (KYMR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kymera Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kymera Therapeutics Inc Shares that will get you 0.0345 shares as per Kymera Therapeutics Inc share price of $43.53 per share as on September 6, 2025 at 1:29 am IST.

What is the minimum amount required to buy Kymera Therapeutics Inc Stock (KYMR) from India?

Indian investors can start investing in Kymera Therapeutics Inc (KYMR) shares with as little as ₹88.143 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.43 in Kymera Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Kymera Therapeutics Inc share’s latest price of $43.53 as on September 6, 2025 at 1:29 am IST, you will get 0.2297 shares of Kymera Therapeutics Inc. Learn more about fractional shares .

What are the returns that Kymera Therapeutics Inc has given to Indian investors in the last 5 years?

Kymera Therapeutics Inc stock has given 47.24% share price returns and 19.81% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?